Welcome to our dedicated page for Madrigal Pharmac news (Ticker: MDGL), a resource for investors and traders seeking the latest updates and insights on Madrigal Pharmac stock.
Madrigal Pharmaceuticals, Inc. (MDGL) is a clinical-stage biopharmaceutical company pioneering treatments for metabolic dysfunction-associated steatohepatitis (MASH), including its FDA-approved therapy Rezdiffra. This page provides investors and healthcare professionals with timely updates on corporate milestones, clinical research, and regulatory developments.
Access the latest press releases, earnings reports, and scientific announcements in one centralized location. Key updates include Rezdiffra's commercialization progress, new clinical data analyses, and strategic partnerships advancing MASH treatment innovation. Our curated news collection ensures you stay informed about material events without speculative commentary.
Regular updates cover regulatory submissions, trial expansions, financial disclosures, and patient access initiatives. Content is rigorously verified to provide accurate, actionable information for investment and therapeutic decision-making. Bookmark this page to monitor Madrigal's progress in addressing critical unmet needs in liver disease therapeutics.
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported strong Q2 2025 financial results, with Rezdiffra net sales reaching $212.8 million. The company achieved several significant milestones, including receiving a new U.S. patent extending Rezdiffra's protection until 2045, securing a $500 million senior secured credit facility, and obtaining a positive CHMP opinion for European approval.
Key financial metrics include cash position of $802.0 million as of June 30, 2025. Operating expenses were $260.0 million, with SG&A expenses at $196.9 million and R&D expenses at $54.1 million. The company expanded its pipeline through a global licensing agreement for an oral GLP-1 development candidate and presented promising two-year F4c MASH clinical data at EASL Congress.
Madrigal Pharmaceuticals (NASDAQ:MDGL) has secured an exclusive global license agreement with CSPC Pharmaceutical Group for SYH2086, a preclinical oral GLP-1 receptor agonist. The deal involves an upfront payment of $120 million and potential milestone payments up to $2 billion, plus royalties.
The agreement aligns with Madrigal's strategy to develop combination treatments for MASH (Metabolic dysfunction-Associated SteatoHepatitis), building upon their foundational therapy Rezdiffra™. Clinical development is planned to begin in first half of 2026. The combination aims to leverage GLP-1's weight loss benefits with Rezdiffra's fibrosis and lipid reduction capabilities in a once-daily oral formulation.
Madrigal Pharmaceuticals (NASDAQ:MDGL), a biopharmaceutical company specializing in treatments for metabolic dysfunction-associated steatohepatitis (MASH), has scheduled its second-quarter 2025 financial results release for August 5, 2025, before U.S. markets open.
The company will host a live webcast at 8:00 AM ET where management will discuss financial and operating results. Participants are advised to register 15 minutes before the webcast, which will be accessible through Madrigal's Investor Relations website. A replay will be available approximately two hours after the live event.
Madrigal Pharmaceuticals (NASDAQ:MDGL) has secured a $500 million senior secured credit facility from Blue Owl Capital managed funds. The non-dilutive financing includes a $350 million initial term loan at closing (partly used to refinance $115 million existing debt), a $150 million delayed draw term loan available through December 2027, and potential additional facilities up to $250 million.
The funding will primarily support MASH (metabolic dysfunction-associated steatohepatitis) pipeline expansion and strategic growth. The company highlighted strong U.S. launch momentum for Rezdiffra, with patent protection through 2044, and an ongoing pivotal F4c outcomes trial.
Madrigal Pharmaceuticals (NASDAQ:MDGL), a biopharmaceutical company focused on MASH therapeutics, announced equity inducement awards to 30 new non-executive employees under its 2025 Inducement Plan. The awards include options to purchase 5,675 shares and 19,863 time-based restricted stock units.
The options were granted at exercise prices of $300.16 (July 1) and $311.14 (July 15) per share. Options vest 25% after one year, followed by 6.25% quarterly thereafter. Restricted stock units vest in four equal annual installments. All awards require continued employment for vesting.
Madrigal Pharmaceuticals (NASDAQ:MDGL) has received a Notice of Allowance from the USPTO for a new patent covering Rezdiffra™ (resmetirom), their FDA-approved treatment for adults with noncirrhotic MASH with moderate to advanced liver fibrosis.
The patent, which will be listed in the FDA's Orange Book, provides protection through September 30, 2044. It specifically covers Rezdiffra's commercial weight-threshold dosing regimen as prescribed in the FDA-approved label. This development strengthens Madrigal's market position as the provider of the first and only FDA-approved treatment for MASH (also known as NASH).
Among patients with clinically significant portal hypertension (CSPH) at baseline, 65% moved to lower risk categories by year two. The study showed a statistically significant mean reduction of 6.7 kPa in liver stiffness, with 51% of patients achieving ≥25% improvement.
Notable outcomes include 35% of patients achieving liver stiffness measurements consistent with F3 fibrosis, suggesting cirrhosis reversal. The drug was well-tolerated, with common side effects including diarrhea, COVID-19, and nausea. The results support the ongoing Phase 3 MAESTRO-NASH OUTCOMES trial of Rezdiffra in compensated MASH cirrhosis.
FAQ
What is the current stock price of Madrigal Pharmac (MDGL)?
What is the market cap of Madrigal Pharmac (MDGL)?
